The systematic name of this enzyme class is (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate:NAD+ oxidoreductase
TRIUMPH-specific exclusions vary by arm and are listed on each trial's ClinicalTrials.gov page
Between 2025 and 2030, the industry anticipates that nearly 200 drugs, including approximately 70 blockbuster medications with annual sales exceeding $1 billion each, will lose their market exclusivity
Fortunately, these side effects are quite rare and its unlikely that you will experience them because most people will go to their doctor long before they experience them
A.SmallC
The GI symptomsnausea, vomiting, diarrhea, constipation, delayed gastric emptyingare present with both drugs and follow a similar dose-escalation pattern